The Department of Health (MDH) published the March 2025 list of drugs of substantial public interest with a focus on insulin products. It is the second list published as part of the statutory reporting requirement. You can also find it on MDH’s Public Interest Drug Lists webpage along with the Public Interest List Methodology & Summary—March 2025. Reporting entities, including pharmacies, have approximately 90 days to report (notifications will be sent 30 or more days after the list release date; reports are due 60 days after notifications are sent). Data and analysis from this and other Lists of Drugs of Substantial Public Interest will be made available on the Prescription Drug Price Transparency website. For direct updates, subscribe to the Prescription Drug Price Transparency email list. For more information, visit the Prescription Drug Price Transparency website.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.